Tashanna Myers - Concepedia

Author

Tashanna Myers

University of Oklahoma Health Sciences Center ORCID

Also Known As

Landrum, Lisa M., T Myers, T. Myers, T.K. Myers, T.K.N. Myers, Tashanna K. Myers, Tashanna K. N. Myers, Tashanna K.N. Myers, Tashanna Myers

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

University of Oklahoma Health Sciences Center Baystate Medical Center Memorial Sloan Kettering Cancer Center Providence College Women & Infants Hospital of Rhode Island

About

Tashanna Myers is an author at University of Oklahoma Health Sciences Center specializing in medicine, oncology, and gynecology oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	380
2	Health Sciences	3	3	111
3	Public Health	1	1	53
4	General Surgery	1	1	24
5	Immunology	1	1	50

Tashanna Myers

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli, Journal of Clinical Oncology	2021	376
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, New England Journal of Medicine	2023	316
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study Joan L. Walker, Mark F. Brady, Lari Wenzel, Journal of Clinical Oncology	2019	228
Ovarian cancer in the octogenarian: Does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Kathleen N. Moore, Monica S. Reid, Daniel N. Fong, Gynecologic Oncology Surgical OncologyGynecological SurgeryMedicineGynecologySurgery	2008	72
Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis Lisa M. Landrum, Kathleen N. Moore, Tashanna Myers, Gynecologic Oncology Similar OutcomesFertilityMedicineReproductive HealthGynecology	2008	53
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Kathleen N. Moore, Antoine Angelergues, Gottfried E. Konecny, Journal of Clinical Oncology Cancer ManagementImmunologyPathologyGynecologyOvarian Cancer	2023	50
A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study Joan L. Walker, Mark F. Brady, Paul DiSilvestro, Gynecologic Oncology Nrg Oncology StudyGastrointestinal OncologyMedicineMetronomic TherapyPhase Iii Trial	2016	41
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO) Bhavana Pothuri, Stephanie V. Blank, Tashanna Myers, Gynecologic Oncology MedicineCancer ManagementCancer DisparityClinical TrialsGynecology	2023	36
LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC) Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli, Annals of Oncology Hematological MalignancyLba31 Primary ResultsMedicineGynecologyImagyn050/gog 3015/Engot-ov39	2020	35
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo Tashanna Myers, Shylet Chengedza, Stan Lightfoot, Investigational New Drugs	2008	33

Page 1